SRR10900546
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- NOTCH_SIGNALING+0.300
- MYOGENESIS+0.200
- UV_RESPONSE_DN+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- APICAL_JUNCTION+0.100
- APICAL_SURFACE+0.100
- BILE_ACID_METABOLISM+0.100
- COMPLEMENT+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
Top 10 suppressed
- MYC_TARGETS_V1-0.600
- MYC_TARGETS_V2-0.600
- DNA_REPAIR-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- E2F_TARGETS-0.400
- G2M_CHECKPOINT-0.400
- GLYCOLYSIS-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- MTORC1_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0E9-01B-11R-A115-07 | — | A | 0.863 |
| 2 | SRR8613705 | — | A | 0.856 |
| 3 | TCGA-AC-A8OS-01A-12R-A41B-07 | — | A | 0.851 |
| 4 | a545f8c1-39e3-48cc-8c22-897c5d3a21ea | — | — | 0.850 |
| 5 | TCGA-CN-5360-01A-01R-1436-07 | — | — | 0.846 |
| 6 | TCGA-86-8668-01A-11R-2403-07 | — | cohortA1 | 0.846 |
| 7 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.844 |
| 8 | C3L-03268 | — | cohortA1 | 0.844 |
| 9 | BS_C80S5N37 | EPN | EPN Tumor | 0.843 |
| 10 | TCGA-50-5942-01A-21R-1755-07 | — | cohortA1 | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |